MAYBE CHARGING CONSUMERS THE LOW PRICE of $599 for a whole human genome sequence is not a winning financial strategy. That’s one possible reason why closely-watched Veritas Genetics of Cambridge, Mass., will stop operations in the United States.
It was in July that Veritas announced it was cutting its already-low price to sequence a genome from
Up to 10,000 patients will get free genetic testing at Northwell Health, the nation’s largest urban health network. In a deal announced on Jan. 9, Northwell Health and Color, a genetic testing company, will collaborate on a program to offer genetic tests to Northwell patients as part of routine primary care. This expands an earlier pilot
IT’S AN ACQUISITION THAT BRINGS TOGETHER two different gene sequencing technologies into one firm. On Nov. 1, Illumina, Inc., announced an agreement to acquire Pacific Biosciences (PacBio) for $1.2 billion.
This deal will bolster Illumina’s already-dominant position in the market for DNA-sequencing machines. Wall Street analysts quickly pointed out that this gives Illumina control of two gene
For readers with a continuing interest in Theranos, the latest development at the troubled lab testing company involves an offer by Founder and CEO, Elizabeth Holmes, to its current shareholders. Various news outlets report that, for existing shareholders who agree not to sue Theranos, Holmes would give them two shares she currently owns for each
Much is happening in the anatomic pathology market in the Pacific Northwest. PAML, LLC (Spokane, Washington), and CellNetix (Seattle, Washington) finally executed the agreement whereby PAML made an equity investment in CellNetix. Now, the two lab companies will collaborate on developing a reference and esoteric anatomic pathology testing service with national ambitions. Within days of
“Pathologists have the opportunity to take on a new clinical role as the integrator
of all that digital pathology information, in combination with the patient’s other clinical data collected from a wide variety of sources.”
—Dirk G. Soenksen, M.S., M.B.A., Founder and CEO, Aperio
CEO Summary: During the 1990s, the pathology profession was exploring ways to use telepathology
CEO SUMMARY: What makes 2010 a watershed year for the laboratory testing industry is enactment of the 2,700-page Patient Protection and Affordable Care Act (PPACA). Even if parts of this bill are repealed, the remaining parts of the massive legislation will trigger major changes to the healthcare system as it operates today. Other stories in
CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagnostic, therapeutic, and prognostic information they contain. GenomeQuest CEO Richard Resnick discusses what is required
CEO SUMMARY: In a pioneering collaboration, the pathology department at Beth Israel Deaconess Medical Center in Boston, Massachusetts, will work with GenomeQuest, Inc., to perform whole genome sequencing of tumor specimens. GenomeQuest will handle sequencing, assembly, and annotation of the genetic data. BIDMC will analyze these whole human genome sequences to develop companion diagnostic tests
CLINICAL LABORATORY ADMINISTRATORS AND SENIOR EXECUTIVES would be well advised to pay close attention to our lead story about the whole human genome sequence collaboration just announced by the pathology department at Beth Israel Deaconess Medical Center (BIDMC) and GenomeQuest, Inc. (See pages 3-6.)
Together, the two organizations intend to be among the first in the